Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B; Correcting Amendment, 9458-9466 [06-1711]

Download as PDF 9458 Federal Register / Vol. 71, No. 37 / Friday, February 24, 2006 / Rules and Regulations paragraph (b) of this section. Other acceptable monitoring approaches include periodic testing approved by EPA or the State or local permitting authority or continuous parameter monitoring as described in paragraph (f) of this section. (f) The owner or operator of a new turbine that commences construction after July 8, 2004, which does not use water or steam injection to control NOX emissions may, but is not required to, perform continuous parameter monitoring as follows: * * * * * (2) For any lean premix stationary combustion turbine, the owner or operator shall continuously monitor the appropriate parameters to determine whether the unit is operating in lowNOX mode. * * * * * (j) For each affected unit that elects to continuously monitor parameters or emissions, or to periodically determine the fuel sulfur content or fuel nitrogen content under this subpart, the owner or operator shall submit reports of excess emissions and monitor downtime, in accordance with § 60.7(c). Excess emissions shall be reported for all periods of unit operation, including startup, shutdown and malfunction. For the purpose of reports required under § 60.7(c), periods of excess emissions and monitor downtime that shall be reported are defined as follows: (1) * * * (iv) For owners or operators that elect, under paragraph (f) of this section, to monitor combustion parameters or parameters that document proper operation of the NOX emission controls: * * * * * (5) All reports required under § 60.7(c) shall be postmarked by the 30th day following the end of each 6month period. 3. Section 60.335 is amended by revising paragraph (b)(8) to read as follows: I § 60.335 Test methods and procedures. wwhite on PROD1PC61 with RULES * * * * * (b) * * * (8) If the owner or operator elects under § 60.334(f) to monitor combustion parameters or parameters indicative of proper operation of NOX emission controls, the appropriate parameters shall be continuously monitored and recorded during each run of the initial performance test, to establish acceptable operating ranges, for purposes of the VerDate Aug<31>2005 18:05 Feb 23, 2006 Jkt 208001 parameter monitoring plan for the affected unit, as specified in § 60.334(g). * * * * * [FR Doc. 06–1743 Filed 2–23–06; 8:45 am] BILLING CODE 6560–50–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services 42 CFR Parts 405, 410, 411, 413, 414, 424 and 426 [CMS–1502–F2 and CMS–1325–F] RIN 0938–AN84 and 098–AN58 Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B; Correcting Amendment Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Correcting amendment to final rule with comment. AGENCY: In the November 21, 2005 Federal Register (70 FR 70116), we published a final rule with comment period entitled ‘‘Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B.’’ This correcting amendment corrects technical errors in the November 21, 2005 publication. EFFECTIVE DATE: This correcting amendment is effective January 1, 2006. FOR FURTHER INFORMATION CONTACT: Diane Milstead, (410) 786–3355. SUPPLEMENTARY INFORMATION: SUMMARY: I. Background FR Doc. 05–22160, entitled ‘‘Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B’’ and appearing in the Federal Register on November 21, 2005 (70 FR 70116), addressed Medicare Part B payment policy, including the physician fee schedule, that is applicable for calendar year (CY) 2006; and finalized certain provisions of the interim final rule to implement the Competitive Acquisition Program (CAP) for Part B Drugs. PO 00000 Frm 00032 Fmt 4700 Sfmt 4700 It also revised Medicare Part B payment and related policies regarding: Physician work, practice expense and malpractice relative value units (RVUs); Medicare telehealth services; multiple diagnostic imaging procedures; covered outpatient drugs and biologicals; supplemental payments to Federally Qualified Health Centers (FQHCs); renal dialysis services; coverage for glaucoma screening services; National Coverage Decision (NCD) timeframes; and physician referrals for nuclear medicine services and supplies to health care entities with which physicians have financial relationships. In addition, the rule finalized the interim RVUs for CY 2005 and issued interim RVUs for new and revised procedure codes for CY 2006. This rule also updated the codes subject to the physician self-referral prohibition and discussed payment policies relating to teaching anesthesia services, therapy caps, private contracts and opt-out, and chiropractic and oncology demonstrations. We have identified a number of technical errors in that final rule with comment period. II. Summary of Errors We are identifying and correcting errors made to certain parts of the preamble, regulations text and addenda of the November 21, 2005 final rule with comment (70 FR 70116). In addition, addendum B, C, D, E and F are revised under this correcting amendment, although these addenda will not appear in the Code of Federal Regulations. A. Summary of Preamble Errors In the preamble text, there were a number of errors and omissions beginning on pages 70150 through 70335. 1. On page 70150, in the first column, in the last paragraph under Section m. (Additional PE Issues Raised by Commenters), in the second sentence, the number of the CPT code referenced is incorrect. 2. On page 70155, in the center column, the last sentence of the second paragraph under the discussion titled, ‘‘3. Cardiac Catheritization and Angioplasty Exception,’’ there was an error in one of the code ranges referenced. 3. On page 70263, in the third column; in last paragraph, the reference to Table 26 is incorrect. 4. On page 70263, Table 26 was numbered incorrectly. 5. On page 70274, in the first column; in the second paragraph language concerning the specific deleted practice E:\FR\FM\24FER1.SGM 24FER1 Federal Register / Vol. 71, No. 37 / Friday, February 24, 2006 / Rules and Regulations wwhite on PROD1PC61 with RULES expense items was inadvertently omitted. 6. On page 70282, in the second column; from the top of the column, lines 8 through 11, the sentence, ‘‘We are assigning a status indicator of N for these services because they are nonvcovered under Medicare.’’ reflects an incorrect status indicator and will be revised. 7. On page 70282, in the third column; we inadvertently omitted a paragraph before section F. (Establishment of Interim PE RVUs for New and Revised Physician’s Current Procedural Terminology (CPT) Codes and New Healthcare Common Procedure Coding System (HCPCS) Codes for 2006). 8. On page 70296, in the second column; in the last paragraph, in line 6, we incorrectly used the term ‘‘PFS’’, and that term will be replaced. 9. On page 70302, in Table 35, the figures for Annual Actual Expenditures and the Cumulative Actual Expenditures, for the period of 1/1/03– 12/31/03, are incorrect and will be revised. 10. On page 70316, the first column, the percentage adjustment referenced in the third complete sentence is incorrect and will be revised. 11. On page 70320, the second footnote to Table 49 has incorrectly listed the numerical scaler. This footnote will be corrected. These corrections are reflected in Section III.A of this correcting amendment. B. Summary of Regulations Text Errors In the regulation text, there were technical errors and omissions in § 405.2469, § 414.190, § 414.904, § 414.906, and § 426.340. 1. On page 70329, in the third column, under § 405.2469, paragraph (a)(1) does not reflect the correct format for amendatory language. Paragraph (a)(1) will be restructured. 2. On page 70331, in the third column, the reference to § 414.190 is incorrect. 3. On page 70332, in the third column, the title (Basis for payment.) for § 414.904 is incorrect. 4. On page 70333, in the first column, under § 414.906, we inadvertently omitted a change to bring the regulations text into conformity with our policy on updating CAP drug prices, as described in the interim final rule with comment period published July 6, 2005. 5. On page 70335, in the first column, under § 426.340, the statutory references in paragraphs (e)(2)(ii) and (f)(2)(ii) are incorrect. VerDate Aug<31>2005 18:05 Feb 23, 2006 Jkt 208001 The corrections are reflected in section III.B. of this correcting amendment. C. Summary of Addendum B, C, D, E and F Errors 1. In Addendum B, pages 70337 through 70463, we are making the following corrections: a. We assigned incorrect RVUs to the following Physicians’ CPT or HCPCS codes: 50000: i. 52648; 60000: ii. 61630, 61635; 80000: iii. 88385–26, 88385–TC, 88385, 88386–26, 88386–TC, and 88386; 90000: iv. 90760, 90761, 90765, 90766, 90767, 90768, 90772, 90773, 90774, 90775, 92626, 92627, 93514, 96401, 96402, 96405, 96406, 96409, 96411, 96413, 96415, 96416, 96417, 96420, 96440, 96450, 96521, 96522, 96542, 97606, 99300, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, and 99337. b. We assigned an incorrect global period for CPT code 92627. c. We assigned incorrect status indicators to the following CPT or codes 0141T, 0142T, 0143T, 88385–26, 88385– TC, 88385, 88386–26, 88386–TC, 88386, 96523, 98960, 98961, 98962 and 99340. d. The following HCPCS codes were inadvertently included: G9041, G9042, G9043 and G9044. These numbers should not have been included because they were not in effect. e. HCPCS code G0332 was inadvertently omitted from the addendum. f. The first footnote to addendum B should be corrected to read ‘‘1CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/ DFARS apply.’’ These corrections are reflected in Sections III.C.1. and 2. of this correcting amendment. 2. In Addendum C, pages 70463 through 70466, we are making the following corrections: a. We assigned incorrect RVUs to the following CPT or alphanumeric HCPCS number for service codes: 60000: i. 61630 and 61635. 80000: ii. 88385–26 and 88386–26. 90000: iii. 90760, 90761, 90765, 90766, 90767, 90768, 90772, 90773, 90774, 90775, 92626, 92627, 96401, 96402, 96409, 96411, 96413, 96415, 96416, PO 00000 Frm 00033 Fmt 4700 Sfmt 4700 9459 96417, 96450, 96521, 96522, 96523, 96542, 99300, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336 and 99337. b. We assigned incorrect status indicators to the following CPT codes 88385–26, 88386–26, 98960, 98961, 98962 and 99340. These corrections are reflected in Section III.C.3 of this correcting amendment. 3. In Addendum D, pages 70466 through 70467, we are correcting the locality name ‘‘Kansas*’’ to read ‘‘Kansas’’. These corrections are reflected in Section III.C.4 of this correcting amendment. 4. In Addendum E, pages 70468 through 70469, we are correcting the locality name ‘‘Kansas*’’ to read ‘‘Kansas’’. These corrections are reflected in Section III.C.5 of this correcting amendment. 5. In Addendum F, pages 70469 through 70471, we are correcting this Addendum by replacing this Addendum in its entirety to address two errors. First, we inadvertently left a discontinued HCPCS code, J1750, on Addendum F. This code was replaced by J1751 and J1752 which are found on Addendum G ‘‘Revised New Drugs for CAP Bidding for 2006’’. Second, we included a new HCPCS code, J7318, which we understood would replace HCPCS codes J7317 and J7320. HCPCS J7318 was not issued and HCPCS codes J7317 & J3120 were retained. We have reweighted and corrected Addendum F to reflect these changes. These corrections are reflected in Section III.C.6 of this correcting amendment. III. Correction of Errors In FR Doc. 05–22160, entitled ‘‘Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B,’’ which appeared in the Federal Register on November 21, 2005 (70 FR 70116), make the following corrections: A. Correction of Preamble Errors 1. On page 70150, in the first column; in the last paragraph under Section m. (Additional PE Issues Raised by Commenters), in the second sentence, the number ‘‘99755’’ is corrected to read ‘‘97755’’. 2. On page 70155, in the center column; the last sentence of the second paragraph under the discussion titled, ‘‘3. Cardiac Catheterization and E:\FR\FM\24FER1.SGM 24FER1 wwhite on PROD1PC61 with RULES 9460 Federal Register / Vol. 71, No. 37 / Friday, February 24, 2006 / Rules and Regulations Angioplasty Exception,’’ the number ‘‘93617’’ is corrected to read ‘‘93618’’. 3. On page 70263, in the third column; in the last paragraph, the phrase ‘‘Table 26’’ is corrected to read ‘‘Table 26A’’. 4. On page 70263, the table heading ‘‘Table 26.—Example of Payments’’ is corrected to read ‘‘Table 26A.—Example of Payments’’. 5. On page 70274, in the first column; in the second paragraph, the paragraph is corrected by adding a new sentence at the end of the paragraph to read as follows: ‘‘Because payment for the supplies and equipment for both of these procedures is provided under a separate DMERC policy, we have deleted the following practice expense items from these codes: Supplies deleted include dressings, both Adaptic and microporous, the drainage canister, and the sharp debridement kit—which was identified as not being needed for the typical scenario; and, the vacuum pump was deleted from the equipment.’’ 6. On page 70282, in the second column; lines 8 through 11, the sentence, ‘‘We are assigning a status indicator of N for these services because they are noncovered under Medicare.’’ is corrected to read, ‘‘We are assigning a status indicator of B for these services because payment for these services is bundled into payment for other Medicare services.’’ 7. On page 70282, in the third column; we are adding a new paragraph before section F. (Establishment of Interim PE RVUs for New and Revised Physician’s Current Procedural Terminology (CPT) Codes and New Healthcare Common Procedure Coding System (HCPCS) Codes for 2006). The new paragraph reads as follows: ‘‘CPT code 99339 Individual physician supervision of patient (patient not present) in home, domiciliary or rest home (e.g., assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment care decisions with health care professional(s), family member(s), surrogate decision maker(s) (e.g., legal guardian) and/or key caregiver(s) involved in patient’s care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 15–29 minutes. CPT code 99340 Individual physician supervision of patient (patient not VerDate Aug<31>2005 18:05 Feb 23, 2006 Jkt 208001 present) in home, domiciliary or rest home (e.g., assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment care decisions with health care professional(s), family member(s), surrogate decision maker(s) (e.g., legal guardian) and/or key caregiver(s) involved inpatient’s care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or more. We are assigning a status indicator of B for these codes because payment for these services is bundled into payment for other services.’’ 8. On page 70296, in the second column; in the last paragraph, in line 6, the term ‘‘PFS’’ is corrected to read ‘‘Code List’’. 9. On page 70302, in Table 35; in the third column titled ‘‘Annual Actual Expenditures’’, in line 10 (1/1/03–12/ 31/03) of that column, ‘‘76.8’’ is corrected to read ‘‘78.2’’; and in the fifth column titled ‘‘Cumulative Actual Expenditures’’, in line 10 (1/1/03–12/ 31/03) of that column, ‘‘460.6’’ is corrected to read ‘‘462.0’’. 10. On page 70316, in the first column; in the third complete sentence, the figure ‘‘¥0.6’’ is corrected to read ‘‘¥0.15’’. 11. On page 70320, in the second footnote to Table 49, the figure ‘‘0.9984’’ is corrected to read ‘‘0.9985’’. B. Correction of Regulation Text Errors List of Subjects 42 CFR Part 405 Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medical devices, Medicare, Reporting and recordkeeping requirements, Rural areas, X-rays. 42 CFR Part 414 Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medicare, Reporting and recordkeeping requirements. 42 CFR Part 426 Administrative practice and procedure, Medicare, Reporting and recordkeeping requirements. Given the errors summarized in section II.B. of this correcting PO 00000 Frm 00034 Fmt 4700 Sfmt 4700 amendment, we are making the following correcting amendments to 42 CFR parts 405, 414, and 426: PART 405—FEDERAL HEALTH INSURANCE FOR THE AGED AND DISABLED 1. The authority citation for part 405 continues to read as follows: I Authority: Secs. 1102, 1861, 1862(a), 1871, 1874, 1881, and 1886(k) of the Social Security Act (42 U.S.C. 1302, 1395x, 1395y(a), 1395hh, 1395kk, 1395rr, and 1395ww(k)), and sec. 353 of the Public Health Service Act (42 U.S.C. 263a). 2. Section 405.2469 is amended by revising paragraph (a)(1) to read as follows: I § 405.2469 Federally Qualified Health Centers supplemental payments. * * * * * (a) Calculation of supplemental payment. (1) The supplemental payment for Federally Qualified Health Center covered services provided to Medicare patients enrolled in Medicare Advantage plans is based on the difference between— (i) Payments received by the center from the Medicare Advantage plan as determined on a per visit basis; and (ii) The Federally Qualified Health Center’s all-inclusive cost-based per visit rate as set forth in this subpart, less any amount the FQHC may charge as described in section 1857(e)(3)(B) of the Act. * * * * * PART 414—PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES 3. The authority citation for part 414 continues to read as follows: I Authority: Secs. 1102, 1871, and 1881(b)(1) of the Social Security Act (42 U.S.C. 1302, 1395hh, and 1395rr(b)(1)). 4. Section 414.906 is amended by revising paragraph (c)(1) introductory text to read as follows: I § 414.906 Competitive acquisition program as the basis of payment. * * * * * (c) Computation of payment amount. (1) Except as specified in paragraph (c)(2) of this section, payment for CAP drugs is based on bids submitted, as a result of the bidding process as described in § 414.910. Based on these bids, a single payment amount for each CAP drug in the competitive acquisition area is determined on the basis of the bids submitted and accepted and updated from the bidding period to the payment year. This single payment amount is then updated on an annual E:\FR\FM\24FER1.SGM 24FER1 Federal Register / Vol. 71, No. 37 / Friday, February 24, 2006 / Rules and Regulations basis based on the approved CAP vendor’s reasonable net acquisition costs for that category as determined by CMS, based, in part, on information disclosed to CMS and limited by the weighted payment amount established under section 1847A of the Act across all drugs for which a composite bid is required in the category, and limited by the payment amount established under section 1847A of the Act for each other drug for which the approved CAP vendor submits a bid in accordance with § 414.910. Adjustment to the payment amounts may be made more often than annually, but no more often than quarterly, in any of the following cases: * * * * * PART 426—REVIEW OF NATIONAL COVERAGE DETERMINATIONS AND LOCAL COVERAGE DETERMINATIONS 5. The authority citation for part 426 continues to read as follows: I Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh). 6. Section 426.340 is amended by revising paragraphs (e)(2)(ii) and (f)(2)(ii) to read as follows: I § 426.340 Procedures for review of new evidence. * * * * * (e) * * * (2) * * * (ii) For NCDs, in compliance with the timeframes specified in section 1862(1) 9461 of the Act, by which CMS completes the reconsideration. (f) * * * (2) * * * (ii) For NCDs, the reconsideration timeframe specified by the Board, in compliance with section 1862(l) of the Act. * * * * * C. Correction of Addendum Errors Given the errors summarized in Section II.C of this correcting amendment, we are making the following corrections to Addendum B, C, D, E, and F. These addenda will not appear in the Code of Federal Regulations. I 1. On pages 70337 through 70463, the following entries to Addendum B are corrected to read as follows: I ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—CONTINUED wwhite on PROD1PC61 with RULES CPT 1/ HCPCS 2 0141T ..... 0142T ..... 0143T ..... ................ 52648 ..... ................ 61630 ..... 61635 ..... ................ 88385 ..... 88385 ..... 88385 ..... 88386 ..... 88386 ..... 88386 ..... ................ 90760 ..... 90761 ..... 90765 ..... 90766 ..... 90767 ..... 90768 ..... 90772 ..... 90773 ..... 90774 ..... 90775 ..... 92626 ..... 92627 ..... ................ 93514 ..... ................ 96401 ..... 96402 ..... 96405 ..... 96406 ..... 96409 ..... 96411 ..... 96413 ..... 96415 ..... 96416 ..... 96417 ..... 96420 ..... ................ 96440 ..... ................ 96450 ..... 96521 ..... 96522 ..... 96523 ..... 96542 ..... ................ 97606 ..... ................ Status Mod ........ ........ ........ 26 TC 26 TC ........ ........ ........ ........ ........ ........ ........ VerDate Aug<31>2005 Description Physician work RVUs 3 Nonfacility PE RVUs Facility PE RVUs Malpractice RVUs Nonfacility total Facility total Global I .......... I .......... I .......... ............ A ........ ............ N ........ N ........ ............ A ........ A ........ A ........ A ........ A ........ A ........ ............ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ ............ C ........ ............ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ ............ A ........ ............ A ........ A ........ A ........ A ........ A ........ ............ A ........ ............ Perq islet transplant ......................... Open islet transplant ........................ Laparoscopic islet transplant ........... .......................................................... Laser surgery of prostate ................. .......................................................... Intracranial angioplasty .................... Intracran angioplasty w/stent ........... .......................................................... Eval molecul probes, 51–250 .......... Eval molecul probes, 51–250 .......... Eval molecul probes, 51–250 .......... Eval molecul probes, 251–500 ........ Eval molecul probes, 251–500 ........ Eval molecul probes, 251–500 ........ .......................................................... Hydration iv infusion init ................... Hydrate iv infusion, add-on .............. Ther/proph/diag iv inf, init ................ Ther/proph/dg iv inf, add-on ............ Tx/proph/dg addl seq iv inf .............. Ther/diag concurrent inf ................... Ther/proph/diag inj, sc/im ................ Ther/proph/diag inj, ia ...................... Ther/proph/diag inj, iv push ............. Ther/proph/diag inj add-on ............... Eval aud status rehab ...................... Evallaud status rehab add-on .......... .......................................................... Left heart catheterization ................. .......................................................... Chemo, anti-neopl, sq/im ................. Chemo hormon antineopl sq/im ....... Chemo intralesional, up to 7 ............ Chemo intralesional over 7 .............. Chemo, iv push, sngl drug ............... Chemo, iv push, addl drug .............. Chemo, iv infusion, 1 hr ................... Chemo, iv infusion, addl hr .............. Chemo prolong infuse w/pump ........ Chemo iv infuse each addl seq ....... Chemo, ia, push technique .............. .......................................................... Chemotherapy, intracavitary ............ .......................................................... Chemotherapy, into CNS ................. Refill/maint, portable pump .............. Refill/maint pump/resvr syst ............. Irrig drug delivery device ................. Chemotherapy injection ................... .......................................................... Neg press wound tx, >50 cm .......... .......................................................... 0.00 0.00 0.00 .................... 11.19 .................... +21.08 +23.08 .................... 1.50 0.00 1.50 1.88 0.00 1.88 .................... 0.17 0.09 0.2 0.18 0.19 0.17 0.17 0.17 0.18 0.10 0.00 0.00 .................... 0.00 .................... 0.2 0.19 0.52 0.80 0.24 0.20 0.28 0.19 0.21 0.2 0.17 .................... 2.37 .................... 1.53 0.21 0.21 0.04 0.75 .................... 0.60 .................... 0.00 0.00 0.00 .................... 74.15 .................... NA NA .................... 0.65 6.45 7.10 0.82 6.23 7.05 .................... 1.43 0.40 11.76 0.46 0.89 0.44 0.31 0.31 1.30 0.57 2.20 0.55 .................... 0.00 .................... 11.17 1.01 2.44 3.02 2.93 1.61 4.20 0.77 4.61 11.95 2.67 .................... 8.15 .................... 6.97 3.77 2.65 0.69 4.26 .................... 0.35 .................... 0.00 0.00 0.00 .................... 4.80 .................... 12.53 13.58 .................... NA NA NA NA NA NA .................... NA NA NA NA NA NA NA NA NA NA NA NA .................... 0.00 .................... NA NA 0.24 0.29 NA NA NA NA NA NA NA .................... 1.23 .................... 1.29 NA NA NA 0.66 .................... 0.24 .................... 0.00 0.00 0.00 .................... 0.79 .................... 2.01 2.20 .................... 0.06 0.06 0.12 0.08 0.08 0.16 .................... 0.07 0.04 0.07 0.04 0.04 0.04 0.01 0.02 0.04 0.04 0.06 .02 .................... 0.00 .................... 0.01 0.01 0.03 0.03 0.06 0.06 0.08 0.07 0.08 0.07 0.08 .................... 0.17 .................... 0.09 0.06 0.06 0.01 0.07 .................... 0.03 .................... 0.00 0.00 0.00 .................... 86.07 .................... NA NA .................... 2.21 6.51 8.72 2.78 6.31 9.09 .................... 1.67 0.53 2.04 0.68 1.12 0.65 0.49 0.50 1.52 0.71 2.26 0.57 .................... 0.00 .................... 1.39 1.21 2.99 3.85 3.23 1.87 4.56 1.03 4.90 2.23 2.92 .................... 10.693.77 .................... 8.59 4.04 2.92 0.74 5.08 .................... 0.98 .................... 0.00 0.00 0.00 .................... 16.78 .................... 35.62 38.86 .................... NA NA NA NA NA NA .................... NA NA NA NA NA NA NA NA NA NA NA NA .................... 0.00 .................... NA NA 0.79 1.12 NA NA NA NA NA NA NA .................... 000 .................... 2.91 NA NA NA 1.48 .................... 0.87 .................... XXX XXX XXX 18:05 Feb 23, 2006 Jkt 208001 PO 00000 Frm 00035 Fmt 4700 Sfmt 4700 E:\FR\FM\24FER1.SGM 24FER1 090 090 090 XXX XXX XXX XXX XXX XXX XXX ZZZ XXX ZZZ ZZZ ZZZ XXX XXX XXX ZZZ XXX ZZZ 000 XXX XXX 000 000 XXX ZZZ XXX ZZZ XXX ZZZ XXX 000 XXX XXX XXX XXX XXX 9462 Federal Register / Vol. 71, No. 37 / Friday, February 24, 2006 / Rules and Regulations ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—CONTINUED CPT 1/ 98960 ..... 98961 ..... 98962 ..... ................ 99300 ..... ................ 99324 ..... 99325 ..... 99326 ..... 99327 ..... 99328 ..... 99334 ..... 99335 ..... 99336 ..... 99337 ..... ................ 99340 ..... ................ G0332 .... Status Mod HCPCS 2 ........ ........ ........ ........ Description Physician work RVUs 3 Nonfacility PE RVUs Facility PE RVUs Malpractice RVUs Nonfacility total Facility total Global B ........ B ........ B ........ ............ A ........ ............ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ ............ B ........ ............ A ........ Self-mgmt educ & train, 1 pt ............ Self-mgmt educ/train, 2–4 pt ........... Self-mgmt educ/train, 5–8 pt ........... .......................................................... lc, infant pbw 2501–5000 gm .......... .......................................................... Domicil/r-home visit new pat ............ Domicil/r-home visit new pat ............ Domicil/r-home visit new pat ............ Domicil/r-home visit new pat ............ Domicil/r-home visit new pat ............ Domicil/r-home visit est pat ............. Domicil/r-home visit est pat ............. Domicil/r-home visit est pat ............. Domicil/r-home visit est pat ............. .......................................................... Domicil/r-home care supervis .......... .......................................................... Preadmin IV immunoglobulin ........... 0.00 0.00 0.00 .................... 2.40 .................... 1.01 1.52 2.27 3.03 3.78 0.76 1.26 2.02 3.03 .................... 0.00 .................... 0.00 0.00 0.00 0.00 .................... NA .................... 0.49 0.68 0.92 1.17 1.42 0.40 0.58 0.82 1.15 .................... 0.00 .................... 1.91 0.00 0.00 0.00 .................... 0.84 .................... NA NA NA NA NA NA NA NA NA .................... 0.00 .................... NA 0.00 0.00 0.00 .................... 0.15 .................... 0.05 0.07 0.10 0.13 0.16 0.04 0.06 0.09 0.13 .................... 0.00 .................... 0.00 0.00 0.00 0.00 .................... NA .................... 1.55 2.27 3.29 4.33 5.36 1.20 1.90 2.93 4.31 .................... 0.00 .................... 1.91 0.00 0.00 0.00 .................... 3.35 .................... NA NA NA NA NA NA NA NA NA .................... 0.00 .................... NA XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX 1 CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply. 2 Copyright 2005 American Dental Association. All Rights Reserved. 3 Indicates RVUs are not used for Medicare payment. 2. On page 70463, the following entries to Addendum B, G9041, G9042, G9043, and G9044 are removed. ADDENDUM B.—RELATIVE VALUE UNITS (RVUS) AND RELATED INFORMATION—CONTINUED CPT 1/ HCPCS 2 Mod Status G9041 G9042 G9043 G9044 ........ ........ ........ ........ X X X X ..... ..... ..... ..... 1 CPT ........ ........ ........ ........ Physician work RVUs 3 Description Low Low Low Low vision vision vision vision rehab occupationa ........ rehab orient/mobi .......... lowvision therapy .......... rehabilate teache .......... 0.00 0.00 0.00 0.00 Nonfacility PE RVUs Facility PE RVUs 0.00 0.00 0.00 0.00 Malpractice RVUs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Nonfacility total 0.00 0.00 0.00 0.00 Facility total 0.00 0.00 0.00 0.00 Global XXX XXX XXX XXX codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply. 2005 American Dental Association. All Rights Reserved. RVUs are not used for Medicare payment. 2 Copyright 3 +Indicates 3. On pages 70463 through 70466, the following entries to Addendum C are corrected to read as follows: I ADDENDUM C.—CODES WITH INTERIM RVUS wwhite on PROD1PC61 with RULES CPT 1/ HCPCS 2 61630 61635 88385 88386 90760 90761 90765 90766 90767 90768 90772 90773 90774 90775 92626 92627 96401 96402 96409 96411 96413 96415 96416 96417 96450 ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... Mod Status 26 26 ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ N N A A A A A A A A A A A A A A A A A A A A A A A VerDate Aug<31>2005 ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ Physician work RVUs 3 Description Intracranial angioplasty ................... Intracran angioplasty w/stent .......... Eval Molecul probes, 51–250 ......... Eval Molecul probes, 251–500 ....... Hydration iv infusion, init ................. Hydrate iv infusion, add-on ............. Ther/proph/diag iv inf, init ............... Ther/proph/dg iv inf, add-on ........... Tx/proph/dg addl seq iv inf ............. Ther/diag concurrent inf .................. Ther/proph/diag inj, sc/im ............... Ther/proph/diag inj, ia ..................... Ther/proph/diag inj, iv push ............ Ther/proph/diag inj add-on .............. Eval aud status rehab ..................... Evalaud status rehab add-on .......... Chemo, anti-neopl, sq/im ................ Chemo hormone antineopl sq/im .... Chemo, iv push, sngl drug .............. Chemo, iv push, addl drug ............. Chemo, iv infusion, 1 hr .................. Chemo, iv infusion, addl hr ............. Chemo prolong infuse w/pump ....... Chemo iv infuse each addl seq ...... Chemotherapy, into CNS ................ 18:05 Feb 23, 2006 Jkt 208001 PO 00000 Frm 00036 +21.08 +23.08 1.50 1.88 0.17 0.09 0.21 0.18 0.19 0.17 0.17 0.17 0.18 0.10 0.00 0.00 0.21 0.19 0.24 0.20 0.28 0.19 0.21 0.21 1.53 Fmt 4700 Nonfacility PE RVUs Facility PE RVUs NA NA 0.65 0.82 1.43 0.40 1.76 0.46 0.89 0.44 0.31 0.31 1.30 0.57 2.20 0.55 1.17 1.01 2.93 1.61 4.20 0.77 4.61 1.95 6.97 Sfmt 4700 Malpractice RVUs 12.53 13.58 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1.29 2.01 2.20 0.06 0.08 0.07 0.04 0.07 0.04 0.04 0.04 0.01 0.02 0.04 0.04 0.06 0.02 0.01 0.01 0.06 0.06 0.08 0.07 0.08 0.07 0.09 E:\FR\FM\24FER1.SGM 24FER1 Nonfacility Total NA NA 2.21 2.78 1.67 0.53 2.04 0.68 1.12 0.65 0.49 0.50 1.52 0.71 2.26 0.57 1.39 1.21 3.23 1.87 4.56 1.03 4.90 2.23 8.59 Facility Total 35.62 30.66 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 2.91 Global 090 090 XXX XXX XXX ZZZ XXX ZZZ ZZZ ZZZ XXX XXX XXX ZZZ XXX ZZZ XXX XXX XXX ZZZ XXX ZZZ XXX ZZZ 000 9463 Federal Register / Vol. 71, No. 37 / Friday, February 24, 2006 / Rules and Regulations ADDENDUM C.—CODES WITH INTERIM RVUS—Continued CPT 1/ HCPCS 2 Mod Status Description Physician work RVUs 3 Nonfacility PE RVUs Facility PE RVUs Malpractice RVUs Nonfacility Total Facility Total 96521 ...... 96522 ...... 96523 ...... 96542 ...... ................. 98960 ...... 98961 ...... 98962 ...... ................. 99300 ...... 99324 ...... 99325 ...... 99326 ...... 99327 ...... 99328 ...... 99334 ...... 99335 ...... 99336 ...... 99337 ...... ................. 99340 ...... ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ A ........ A ........ A ........ A ........ ............ B ........ B ........ B ........ ............ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ A ........ ............ B ........ Refill/maint, portable pump ............. Refil/maint pump/resvr syst ............ Irrig drug delivery device ................ Chemotherapy injection .................. ......................................................... Self-mgmt educ & train, 1 pt ........... Self-mgmt educ/train, 2–4 pt .......... Self-mgmt educ/train 5–8 pt ........... ......................................................... Ic, infant pbw 2501–5000 gm ......... Domicil/r-home visit new pat ........... Domicil/r-home visit new pat ........... Domicil/r-home visit new pat ........... Domicil/r-home visit new pat ........... Domicil/r-home visit new pat ........... Domicil/r-home visit est pat ............ Domicil/r-home visit est pat ............ Domicil/r-home visit est pat ............ Domicil/r-home visit est pat ............ ......................................................... Domicil/r-home care supervis ......... 0.21 0.21 0.04 0.75 .................... 0.00 0.00 0.00 .................... 2.40 1.01 1.52 2.27 3.03 3.78 0.76 1.26 2.02 3.03 .................... 0.00 3.77 2.65 0.69 4.26 .................... 0.00 0.00 0.00 .................... NA 0.49 0.68 0.92 1.17 1.42 0.40 0.58 0.82 1.15 .................... 0.00 NA NA NA 0.66 .................... 0.00 0.00 0.00 .................... 0.84 NA NA NA NA NA NA NA NA NA .................... 0.00 0.06 0.06 0.01 0.07 .................... 0.00 0.00 0.00 .................... 0.15 0.05 0.07 0.10 0.13 0.16 0.04 0.06 0.09 0.13 .................... 0.00 4.04 2.92 0.74 5.08 .................... 0.00 0.00 0.00 .................... NA 1.55 2.27 3.29 4.33 5.36 1.20 1.90 2.93 4.31 .................... 0.00 NA NA NA 1.48 .................... 0.00 0.00 0.00 .................... 3.35 NA NA NA NA NA NA NA NA NA .................... 0.00 Global XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX XXX 1 CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply. 2 Copyright 2005 American Dental Association. All Rights Reserved. 3 +Indicates RVUs are not used for Medicare payment. 4. On page 70467, in Addendum D, in the 11th entry, in the third column, the I locality ‘‘Kansas*’’ is corrected to read ‘‘Kansas’’ as follows: ADDENDUM D.—2006 GEOGRAPHIC PRACTICE COST INDICES BY MEDICARE CARRIER AND LOCALITY—CONTINUED Carrier Locality 00650 ........................................................ 00 5. On page 70469, in Addendum E, in the fourth entry, in the third column, I Locality name Work GPCI Kansas ...................................................... 1.000 PE GPCI 0.878 MP GPCI 0.721 the locality ‘‘Kansas*’’ is corrected to read ‘‘Kansas’’ as follows: ADDENDUM E.—2006 GAFS—CONTINUED Carrier Locality 00650 ................................................................................ Locality name 00 Kansas ............................................................................. 2006 GAF 0.0936 6. On pages 70469 through 70471, Addendum F, in its entirety, is corrected to read as follows: I ADDENDUM F.—REVISED SINGLE DRUG CATEGORY LIST wwhite on PROD1PC61 with RULES HCPCS J0150 J0152 J0170 J0207 J0215 J0280 J0290 J0475 J0540 J0550 J0570 J0585 J0587 J0600 J0637 J0640 J0670 Long description ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ VerDate Aug<31>2005 18:05 Feb 23, 2006 Jkt 208001 Weight Injection, adenosine for therapeutic use, 6 mg ........................................................... Injection, adenosine for diagnostic use, 30 mg ........................................................... Injection, adrenalin, epinephrine, 1 ml ampule ............................................................ Injection, amifostine, 500 mg ....................................................................................... Injection, alefacept, 0.5 mg .......................................................................................... Injection, aminophyllin, 250 mg ................................................................................... Injection, ampicillin sodium, 500 mg ............................................................................ Injection, baclofen, 10 mg ............................................................................................ Injection, penicillin g benzathine and penicillin g procaine, 1,200,000 units ............... Injection, penicillin g benzathine and penicillin g procaine, 2,400,000 units ............... Injection, penicillin g benzathine, 1,200,000 units ....................................................... Botulinum toxin type A, per unit ................................................................................... Botulinum toxin type B, per 100 units .......................................................................... Injection, edetate calcium disodium, 1000 mg ............................................................ Injection, caspofungin acetate, 5 mg ........................................................................... Injection, leucovorin calcium, per 50 mg ..................................................................... Injection, mepivacaine hydrochloride, per 10 ml ......................................................... PO 00000 Frm 00037 Fmt 4700 Sfmt 4700 E:\FR\FM\24FER1.SGM 24FER1 0.00070000 0.00459478 0.00007897 0.00016099 0.00083383 0.00082088 0.00012657 0.00024643 0.00007209 0.00001831 0.00004605 0.03743206 0.00150704 0.00004459 0.00008483 0.01064503 0.00038398 9464 Federal Register / Vol. 71, No. 37 / Friday, February 24, 2006 / Rules and Regulations ADDENDUM F.—REVISED SINGLE DRUG CATEGORY LIST—Continued wwhite on PROD1PC61 with RULES HCPCS J0690 J0692 J0696 J0698 J0702 J0704 J0735 J0800 J0881 J0885 J0895 J1000 J1020 J1030 J1040 J1051 J1094 J1100 J1190 J1200 J1212 J1245 J1250 J1260 J1335 J1440 J1441 J1450 J1580 J1600 J1626 J1631 J1642 J1644 J1645 J1650 J1655 J1720 J1745 J1756 J1885 J1940 J1956 J2001 J2010 J2150 J2260 J2300 J2325 J2353 J2354 J2405 J2430 J2505 J2550 J2680 J2765 J2780 J2820 J2912 J2916 J2920 J2930 J2997 J3260 J3301 J3302 J3303 J3315 J3370 J3396 J3410 Long description ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ VerDate Aug<31>2005 18:05 Feb 23, 2006 Jkt 208001 Weight Injection, cefazolin sodium, 500 mg ............................................................................ Injection, cefepime hydrochloride, 500 mg .................................................................. Injection, ceftriaxone sodium, per 250 mg ................................................................... Injection, cefotaxime sodium, per gm .......................................................................... Injection, betamethasone acetate & betamethasone sodium phosphate, per 3 mg ... Injection, betamethasone sodium phosphate, per 4 mg ............................................. Injection, clonidine hydrochloride, 1 mg ...................................................................... Injection, corticotropin, 40 units ................................................................................... Injection, darbepoetin alfa, 1 mcg (non-ESRD use) .................................................... Injection, epoetin alpha, (for non ESRD use), per 1000 units .................................... Injection, deferoxamine mesylate, 500 mg .................................................................. Injection, depo-estradiol cypionate, 5 mg .................................................................... Injection, methylprednisolone acetate, 20 mg ............................................................. Injection, methylprednisolone acetate, 40 mg ............................................................. Injection, methylprednisolone acetate, 80 mg ............................................................. Injection, medroxyprogesterone acetate, 50 mg ......................................................... Injection, dexamethasone acetate, 1 mg ..................................................................... Injection, dexamethasone sodium phosphate, 1 mg ................................................... Injection, dexrazoxane hydrochloride, per 250 mg ...................................................... Injection, diphenhydramine hcl, 50 mg ........................................................................ Injection, DMSO, dimethyl sulfoxide, 50%, 50 ml ....................................................... Injection, dipyridamole, per 10 mg ............................................................................... Injection, dobutamine hydrochloride, per 250 mg ....................................................... Injection, dolasetron mesylate, 10 mg ......................................................................... Injection, ertapenem sodium, 500 mg ......................................................................... Injection, filgrastim (G–CSF), 300 mcg ........................................................................ Injection, filgrastim (G–CSF), 480 mcg ........................................................................ Injection fluconazole, 200 mg ...................................................................................... Injection, garamycin, gentamicin, 80 mg ..................................................................... Injection, gold sodium thiomalate, 50 mg .................................................................... Injection, granisetron hydrochloride, 100 mcg ............................................................. Injection, haloperidol decanoate, per 50 mg ............................................................... Injection, heparin sodium, (heparin lock flush), per 10 units ....................................... Injection, heparin sodium, per 1000 units .................................................................... Injection, dalteparin sodium, per 2500 iu ..................................................................... Injection, enoxaparin sodium, 10 mg ........................................................................... Injection, tinzaparin sodium, 1000 iu ........................................................................... Injection, hydrocortisone sodium succinate, 100 mg ................................................... Injection infliximab, 10 mg ........................................................................................... Injection, iron sucrose, 1 mg ........................................................................................ Injection, ketorolac tromethamine, per 15 mg ............................................................. Injection, furosemide, 20 mg ........................................................................................ Injection, levofloxacin, 250 mg ..................................................................................... Injection, lidocaine hcl for intravenous infusion, 10 mg ............................................... Injection, lincomycin hcl, 300 mg ................................................................................. Injection, mannitol, 25% in 50 ml ................................................................................. Injection, milrinone lactate, 5 mg ................................................................................. Injection, nalbuphine hydrochloride, per 10 mg ........................................................... Injection, nesiritide, 0.1 mg .......................................................................................... Injection, octreotide, depot form for intramuscular injection, 1 mg ............................. Injection, octreotide, non-depot subcutaneous or intravenous injection, 25 mcg ....... Injection, ondansetron hydrochloride, per 1 mg .......................................................... Injection, pamidronate disodium, per 30 mg ............................................................... Injection, pegfilgrastim, 6 mg ....................................................................................... Injection, promethazine hcl, 50 mg .............................................................................. Injection, fluphenazine decanoate, 25 mg ................................................................... Injection, metoclopramide hCL, 10 mg ........................................................................ Injection, ranitidine hydrochloride, 25 mg .................................................................... Injection, sargramostim (GM–CSF), 50 mcg ............................................................... Injection, sodium chloride, 0.9%, per 2 ml .................................................................. Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg .................. Injection, methylprednisolone sodium succinate, 40 mg ............................................. Injection, methylprednisolone sodium succinate, 125 mg ........................................... Injection, alteplase recombinant, 1 mg ........................................................................ Injection, tobramycin sulfate, 80 mg ............................................................................ Injection, triamcinolone acetonide, per 10 mg ............................................................. Injection, triamcinolone diacetate, per 5 mg ................................................................ Injection, triamcinolone hexacetonide, per 5 mg ......................................................... Injection, triptorelin pamoate, 3.75 mg ........................................................................ Injection, vancomycin hCL, 500 mg ............................................................................. Injection, verteporfin, 0.1 mg ....................................................................................... Injection, hydroxyzine hCL, 25 mg .............................................................................. PO 00000 Frm 00038 Fmt 4700 Sfmt 4700 E:\FR\FM\24FER1.SGM 24FER1 0.00042410 0.00024846 0.00668833 0.00014878 0.00287709 0.00057059 0.00034149 0.00363945 0.15953454 0.25136609 0.00024448 0.00021013 0.00127329 0.00593138 0.00527803 0.00006526 0.00351268 0.05492057 0.00002444 0.00216491 0.00008475 0.00383178 0.00053182 0.01737101 0.00013263 0.00193572 0.00407388 0.00001609 0.00039937 0.00005613 0.01483731 0.00020702 0.06422737 0.00354562 0.00011526 0.00135618 0.00047170 0.00013327 0.02762721 0.01026994 0.00330082 0.00065369 0.00008629 0.00077528 0.00062461 0.00029211 0.00004959 0.00026341 0.00027406 0.00195107 0.00008412 0.01373037 0.00156790 0.00065114 0.00068681 0.00015113 0.00011134 0.00088550 0.00217910 0.00680009 0.00061134 0.00031230 0.00077199 0.00012239 0.00018292 0.02166537 0.00173214 0.00094603 0.00000713 0.00084187 0.05438624 0.00041004 Federal Register / Vol. 71, No. 37 / Friday, February 24, 2006 / Rules and Regulations 9465 ADDENDUM F.—REVISED SINGLE DRUG CATEGORY LIST—Continued wwhite on PROD1PC61 with RULES HCPCS J3420 J3475 J3480 J3487 J7030 J7040 J7042 J7050 J7060 J7070 J7120 J7317 J7320 J9000 J9001 J9031 J9040 J9045 J9050 J9060 J9062 J9065 J9070 J9080 J9090 J9091 J9092 J9093 J9094 J9095 J9096 J9097 J9098 J9100 J9110 J9130 J9140 J9150 J9170 J9178 J9181 J9182 J9185 J9190 J9200 J9201 J9202 J9206 J9208 J9209 J9211 J9213 J9214 J9219 J9245 J9250 J9260 J9263 J9265 J9268 J9280 J9290 J9291 J9293 J9310 J9320 J9340 J9350 J9355 J9360 J9370 J9375 Long description ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ ........................................................ VerDate Aug<31>2005 18:05 Feb 23, 2006 Jkt 208001 Weight Injection, vitamin B–12 cyanocobalamin, up to 1000 mcg .......................................... Injection, magnesium sulfate, per 500 mg ................................................................... Injection, potassium chloride, per 2 meq ..................................................................... Injection, zoledronic acid, 1 mg ................................................................................... Infusion, normal saline solution, 1000 cc .................................................................... Infusion, normal saline solution, sterile (500 ml = 1 unit) ............................................ 5% dextrose/normal saline (500 ml = 1 unit) ............................................................... Infusion, normal saline solution, 250 cc ...................................................................... 5% dextrose/water (500 ml = 1 unit) ........................................................................... Infusion, D5W, 1000 cc ................................................................................................ Ringers lactate infusion, 1000 cc ................................................................................. Sodium hyaluronate, per 20 to 25 mg dose for intra-articular injection ...................... Hylan G–F 20, 16 mg, for intra articular injection ....................................................... Doxorubicin hCL, 10 mg .............................................................................................. Doxorubicin hydrochloride, all lipid formulations, 10 mg ............................................. BCG (Intravesical) per instillation ................................................................................ Bleomycin sulfate, 15 units .......................................................................................... Carboplatin, 50 mg ....................................................................................................... Carmustine, 100 mg ..................................................................................................... Cisplatin, powder or solution, per 10 mg ..................................................................... Cisplatin, 50 mg ........................................................................................................... Injection, cladribine, per 1 mg ...................................................................................... Cyclophosphamide, 100 mg ........................................................................................ Cyclophosphamide, 200 mg ........................................................................................ Cyclophosphamide, 500 mg ........................................................................................ Cyclophosphamide, 1.0 gram ...................................................................................... Cyclophosphamide, 2.0 gram ...................................................................................... Cyclophosphamide, lyophilized, 100 mg ..................................................................... Cyclophosphamide, lyophilized, 200 mg ..................................................................... Cyclophosphamide, lyophilized, 500 mg ..................................................................... Cyclophosphamide, lyophilized, 1.0 gram ................................................................... Cyclophosphamide, lyophilized, 2.0 gram ................................................................... Cytarabine liposome, 10 mg ........................................................................................ Cytarabine, 100 mg ...................................................................................................... Cytarabine, 500 mg ...................................................................................................... Dacarbazine, 100 mg ................................................................................................... Dacarbazine, 200 mg ................................................................................................... Daunorubicin, 10 mg .................................................................................................... Docetaxel, 20 mg ......................................................................................................... Injection, epirubicin hCL, 2 mg .................................................................................... Etoposide, 10 mg ......................................................................................................... Etoposide, 100 mg ....................................................................................................... Fludarabine phosphate, 50 mg .................................................................................... Fluorouracil, 500 mg .................................................................................................... Floxuridine, 500 mg ..................................................................................................... Gemcitabine hCL, 200 mg ........................................................................................... Goserelin acetate implant, per 3.6 mg ........................................................................ Irinotecan, 20 mg ......................................................................................................... Ifosfamide, 1 gm .......................................................................................................... Mesna, 200 mg ............................................................................................................ Idarubicin hydrochloride, 5 mg ..................................................................................... Interferon, ALFA–2A, recombinant, 3 million units ...................................................... Interferon, ALFA–2B, recombinant, 1 million units ...................................................... Leuprolide acetate implant, 65 mg .............................................................................. Injection, melphalan hydrochloride, 50 mg .................................................................. Methotrexate sodium, 5 mg ......................................................................................... Methotrexate sodium, 50 mg ....................................................................................... Injection, oxaliplatin, 0.5 mg ........................................................................................ Paclitaxel, 30 mg .......................................................................................................... Pentostatin, per 10 mg ................................................................................................. Mitomycin, 5 mg ........................................................................................................... Mitomycin, 20 mg ......................................................................................................... Mitomycin, 40 mg ......................................................................................................... Injection, mitoxantrone hydrochloride, per 5 mg ......................................................... Rituximab, 100 mg ....................................................................................................... Streptozocin, 1 gm ....................................................................................................... Thiotepa, 15 mg ........................................................................................................... Topotecan, 4 mg .......................................................................................................... Trastuzumab, 10 mg .................................................................................................... Vinblastine sulfate, 1 mg .............................................................................................. Vincristine sulfate, 1 mg ............................................................................................... Vincristine sulfate, 2 mg ............................................................................................... PO 00000 Frm 00039 Fmt 4700 Sfmt 4700 E:\FR\FM\24FER1.SGM 24FER1 0.01203050 0.00108505 0.00215709 0.00336479 0.00102834 0.00243166 0.00049872 0.00993344 0.00102860 0.00015894 0.00016980 0.00191598 0.00149854 0.00235846 0.00032536 0.00049267 0.00003728 0.00570096 0.00000890 0.00095393 0.00025430 0.00008142 0.00062691 0.00004968 0.00008125 0.00005049 0.00000530 0.00092680 0.00009190 0.00017696 0.00013977 0.00001360 0.00000817 0.00013010 0.00002076 0.00009429 0.00007024 0.00000490 0.00257221 0.00121917 0.00231466 0.00053112 0.00030647 0.00396193 0.00000409 0.00496182 0.00288597 0.00319095 0.00007892 0.00036868 0.00000318 0.00008082 0.00675198 0.00006526 0.00000159 0.00186700 0.00051449 0.07318565 0.00556692 0.00000645 0.00004077 0.00003481 0.00006143 0.00025120 0.00409565 0.00000673 0.00002452 0.00018268 0.00543348 0.00035813 0.00019751 0.00011515 9466 Federal Register / Vol. 71, No. 37 / Friday, February 24, 2006 / Rules and Regulations ADDENDUM F.—REVISED SINGLE DRUG CATEGORY LIST—Continued HCPCS Long description J9390 ........................................................ J9395 ........................................................ J9600 ........................................................ Q3025 ....................................................... Vinorelbine tartrate, per 10 mg .................................................................................... Injection, fulvestrant, 25 mg ......................................................................................... Porfimer sodium, 75 mg ............................................................................................... Injection, interferon BETA–1A, 11 mcg for intramuscular use .................................... wwhite on PROD1PC61 with RULES IV. Waiver of Proposed Rulemaking and Delay in Effective Date We ordinarily publish a notice of proposed rulemaking in the Federal Register to provide a period for public comment before the provisions of a rule take effect in accordance with section 553(b) of the Administrative Procedure Act (APA) (5 U.S.C. 553(b)). However, we can waive the notice and comment procedures if the Secretary finds, for good cause, that the notice and comment process is impracticable, unnecessary or contrary to the public interest, and incorporates a statement of the finding and the reasons therefore in the rule. We can also waive the 30-day delay in effective date under the APA (5 U.S.C. 553(d)) when there is good cause to do so and we publish in the rule an explanation of our good cause. This correcting amendment addresses technical errors and omissions made in FR Doc. 05–22160, entitled ‘‘Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B,’’ which appeared in the Federal Register on November 21, 2005 (70 FR 70116) and was made effective January 1, 2006. The provisions of this final rule with comment period have been previously subjected to notice and comment procedures. These corrections are consistent with the discussion and text and do not make substantive changes to the CY 2006 published rule. As such, this correcting amendment is intended to ensure the CY 2006 final rule with comment accurately reflects the policy adopted. Therefore, we find that undertaking further notice and comment procedures to incorporate these corrections into the final rule with comment is unnecessary and contrary to the public interest. For the same reasons, we are also waiving the 30-day delay in effective date for this correcting amendment. We believe that it is in the public interest to ensure that the CY 2006 final rule with comment accurately states our policy on physician fee schedule and other Part B payment policies, and provisions related to the competitive VerDate Aug<31>2005 18:05 Feb 23, 2006 Jkt 208001 acquisition program of outpatient drugs and biologicals under Part B. Therefore, delaying the effective date of these corrections beyond the January 1, 2006 effective date of the final rule with comment period would be contrary to the public interest. In so doing, we find good cause to waive the 30-day delay in the effective date. (Catalog of Federal Domestic Assistance Program No. 93.774, Medicare— Supplementary Medical Insurance Program) Dated: February 7, 2006. Ann C. Agnew, Executive Secretary to the Department. [FR Doc. 06–1711 Filed 2–23–06; 8:45 am] BILLING CODE 4120–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services 42 CFR Parts 411 and 489 [CMS–6272–IFC] RIN 0938–AN27 Medicare Program; Medicare Secondary Payer Amendments Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Interim final rule with comment period. AGENCY: SUMMARY: This interim final rule with comment period implements amendments to the Medicare Secondary Payer (MSP) provisions under Title III of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). The MMA amendments clarify the MSP provisions regarding the obligations of primary plans and primary payers, the nature of the insurance arrangements subject to the MSP rules, the circumstances under which Medicare may make conditional payments, and the obligations of primary payers to reimburse Medicare. DATES: Effective date: These regulations are effective on April 25, 2006. Comment date: To be assured consideration, comments must be received at one of the addresses PO 00000 Frm 00040 Fmt 4700 Sfmt 4700 Weight 0.00111035 0.00126670 0.00000030 0.00078263 provided below, no later than 5 p.m. on April 25, 2006. ADDRESSES: In commenting, please refer to file code CMS–6272–IFC. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission. You may submit comments in one of four ways (no duplicates, please): 1. Electronically. You may submit electronic comments on specific issues in this regulation to https:// www.cms.hhs.gov/eRulemaking. Click on the link ‘‘Submit electronic comments on CMS regulations with an open comment period.’’ (Attachments should be in Microsoft Word, WordPerfect, or Excel; however, we prefer Microsoft Word.) 2. By regular mail. You may mail written comments (one original and two copies) to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–6272– IFC, g1P.O. Box 8017, Baltimore, MD 21244–8017. Please allow sufficient time for mailed comments to be received before the close of the comment period. 3. By express or overnight mail. You may send written comments (one original and two copies) to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–6272–IFC, Mail Stop C4–26–05, 7500 Security Boulevard, Baltimore, MD 21244–1850. 4. By hand or courier. If you prefer, you may deliver (by hand or courier) your written comments (one original and two copies) before the close of the comment period to one of the following addresses. If you intend to deliver your comments to the Baltimore address, please call telephone number (410) 786– 7195 in advance to schedule your arrival with one of our staff members. Room 445–G, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201; or 7500 Security Boulevard, Baltimore, MD 21244–1850. (Because access to the interior of the HHH Building is not readily available to persons without Federal Government identification, commenters are encouraged to leave their comments in E:\FR\FM\24FER1.SGM 24FER1

Agencies

[Federal Register Volume 71, Number 37 (Friday, February 24, 2006)]
[Rules and Regulations]
[Pages 9458-9466]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-1711]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 405, 410, 411, 413, 414, 424 and 426

[CMS-1502-F2 and CMS-1325-F]
RIN 0938-AN84 and 098-AN58


Medicare Program; Revisions to Payment Policies Under the 
Physician Fee Schedule for Calendar Year 2006 and Certain Provisions 
Related to the Competitive Acquisition Program of Outpatient Drugs and 
Biologicals Under Part B; Correcting Amendment

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Correcting amendment to final rule with comment.

-----------------------------------------------------------------------

SUMMARY: In the November 21, 2005 Federal Register (70 FR 70116), we 
published a final rule with comment period entitled ``Medicare Program; 
Revisions to Payment Policies Under the Physician Fee Schedule for 
Calendar Year 2006 and Certain Provisions Related to the Competitive 
Acquisition Program of Outpatient Drugs and Biologicals Under Part B.'' 
This correcting amendment corrects technical errors in the November 21, 
2005 publication.

EFFECTIVE DATE: This correcting amendment is effective January 1, 2006.

FOR FURTHER INFORMATION CONTACT: Diane Milstead, (410) 786-3355.

SUPPLEMENTARY INFORMATION:

I. Background

    FR Doc. 05-22160, entitled ``Medicare Program; Revisions to Payment 
Policies Under the Physician Fee Schedule for Calendar Year 2006 and 
Certain Provisions Related to the Competitive Acquisition Program of 
Outpatient Drugs and Biologicals Under Part B'' and appearing in the 
Federal Register on November 21, 2005 (70 FR 70116), addressed Medicare 
Part B payment policy, including the physician fee schedule, that is 
applicable for calendar year (CY) 2006; and finalized certain 
provisions of the interim final rule to implement the Competitive 
Acquisition Program (CAP) for Part B Drugs.
    It also revised Medicare Part B payment and related policies 
regarding: Physician work, practice expense and malpractice relative 
value units (RVUs); Medicare telehealth services; multiple diagnostic 
imaging procedures; covered outpatient drugs and biologicals; 
supplemental payments to Federally Qualified Health Centers (FQHCs); 
renal dialysis services; coverage for glaucoma screening services; 
National Coverage Decision (NCD) timeframes; and physician referrals 
for nuclear medicine services and supplies to health care entities with 
which physicians have financial relationships.
    In addition, the rule finalized the interim RVUs for CY 2005 and 
issued interim RVUs for new and revised procedure codes for CY 2006. 
This rule also updated the codes subject to the physician self-referral 
prohibition and discussed payment policies relating to teaching 
anesthesia services, therapy caps, private contracts and opt-out, and 
chiropractic and oncology demonstrations.
    We have identified a number of technical errors in that final rule 
with comment period.

II. Summary of Errors

    We are identifying and correcting errors made to certain parts of 
the preamble, regulations text and addenda of the November 21, 2005 
final rule with comment (70 FR 70116). In addition, addendum B, C, D, E 
and F are revised under this correcting amendment, although these 
addenda will not appear in the Code of Federal Regulations.

A. Summary of Preamble Errors

    In the preamble text, there were a number of errors and omissions 
beginning on pages 70150 through 70335.
    1. On page 70150, in the first column, in the last paragraph under 
Section m. (Additional PE Issues Raised by Commenters), in the second 
sentence, the number of the CPT code referenced is incorrect.
    2. On page 70155, in the center column, the last sentence of the 
second paragraph under the discussion titled, ``3. Cardiac 
Catheritization and Angioplasty Exception,'' there was an error in one 
of the code ranges referenced.
    3. On page 70263, in the third column; in last paragraph, the 
reference to Table 26 is incorrect.
    4. On page 70263, Table 26 was numbered incorrectly.
    5. On page 70274, in the first column; in the second paragraph 
language concerning the specific deleted practice

[[Page 9459]]

expense items was inadvertently omitted.
    6. On page 70282, in the second column; from the top of the column, 
lines 8 through 11, the sentence, ``We are assigning a status indicator 
of N for these services because they are nonvcovered under Medicare.'' 
reflects an incorrect status indicator and will be revised.
    7. On page 70282, in the third column; we inadvertently omitted a 
paragraph before section F. (Establishment of Interim PE RVUs for New 
and Revised Physician's Current Procedural Terminology (CPT) Codes and 
New Healthcare Common Procedure Coding System (HCPCS) Codes for 2006).
    8. On page 70296, in the second column; in the last paragraph, in 
line 6, we incorrectly used the term ``PFS'', and that term will be 
replaced.
    9. On page 70302, in Table 35, the figures for Annual Actual 
Expenditures and the Cumulative Actual Expenditures, for the period of 
1/1/03-12/31/03, are incorrect and will be revised.
    10. On page 70316, the first column, the percentage adjustment 
referenced in the third complete sentence is incorrect and will be 
revised.
    11. On page 70320, the second footnote to Table 49 has incorrectly 
listed the numerical scaler. This footnote will be corrected.
    These corrections are reflected in Section III.A of this correcting 
amendment.

B. Summary of Regulations Text Errors

    In the regulation text, there were technical errors and omissions 
in Sec.  405.2469, Sec.  414.190, Sec.  414.904, Sec.  414.906, and 
Sec.  426.340.
    1. On page 70329, in the third column, under Sec.  405.2469, 
paragraph (a)(1) does not reflect the correct format for amendatory 
language. Paragraph (a)(1) will be restructured.
    2. On page 70331, in the third column, the reference to Sec.  
414.190 is incorrect.
    3. On page 70332, in the third column, the title (Basis for 
payment.) for Sec.  414.904 is incorrect.
    4. On page 70333, in the first column, under Sec.  414.906, we 
inadvertently omitted a change to bring the regulations text into 
conformity with our policy on updating CAP drug prices, as described in 
the interim final rule with comment period published July 6, 2005.
    5. On page 70335, in the first column, under Sec.  426.340, the 
statutory references in paragraphs (e)(2)(ii) and (f)(2)(ii) are 
incorrect.
    The corrections are reflected in section III.B. of this correcting 
amendment.

C. Summary of Addendum B, C, D, E and F Errors

    1. In Addendum B, pages 70337 through 70463, we are making the 
following corrections:
    a. We assigned incorrect RVUs to the following Physicians' CPT or 
HCPCS codes:

50000:
    i. 52648;
60000:
    ii. 61630, 61635;
80000:
    iii. 88385-26, 88385-TC, 88385, 88386-26, 88386-TC, and 88386;
90000:
    iv. 90760, 90761, 90765, 90766, 90767, 90768, 90772, 90773, 90774, 
90775, 92626, 92627, 93514, 96401, 96402, 96405, 96406, 96409, 96411, 
96413, 96415, 96416, 96417, 96420, 96440, 96450, 96521, 96522, 96542, 
97606, 99300, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 
and 99337.

    b. We assigned an incorrect global period for CPT code 92627.
    c. We assigned incorrect status indicators to the following CPT or 
codes 0141T, 0142T, 0143T, 88385-26, 88385-TC, 88385, 88386-26, 88386-
TC, 88386, 96523, 98960, 98961, 98962 and 99340.
    d. The following HCPCS codes were inadvertently included: G9041, 
G9042, G9043 and G9044. These numbers should not have been included 
because they were not in effect.
    e. HCPCS code G0332 was inadvertently omitted from the addendum.
    f. The first footnote to addendum B should be corrected to read 
``\1\CPT codes and descriptions only. Copyright 2005 American Medical 
Association. All Rights Reserved. Applicable FARS/DFARS apply.''
    These corrections are reflected in Sections III.C.1. and 2. of this 
correcting amendment.
    2. In Addendum C, pages 70463 through 70466, we are making the 
following corrections:
    a. We assigned incorrect RVUs to the following CPT or alphanumeric 
HCPCS number for service codes:

60000:
    i. 61630 and 61635.
80000:
    ii. 88385-26 and 88386-26.
90000:
    iii. 90760, 90761, 90765, 90766, 90767, 90768, 90772, 90773, 90774, 
90775, 92626, 92627, 96401, 96402, 96409, 96411, 96413, 96415, 96416, 
96417, 96450, 96521, 96522, 96523, 96542, 99300, 99324, 99325, 99326, 
99327, 99328, 99334, 99335, 99336 and 99337.

    b. We assigned incorrect status indicators to the following CPT 
codes 88385-26, 88386-26, 98960, 98961, 98962 and 99340.
    These corrections are reflected in Section III.C.3 of this 
correcting amendment.
    3. In Addendum D, pages 70466 through 70467, we are correcting the 
locality name ``Kansas*'' to read ``Kansas''.
    These corrections are reflected in Section III.C.4 of this 
correcting amendment.
    4. In Addendum E, pages 70468 through 70469, we are correcting the 
locality name ``Kansas*'' to read ``Kansas''.
    These corrections are reflected in Section III.C.5 of this 
correcting amendment.
    5. In Addendum F, pages 70469 through 70471, we are correcting this 
Addendum by replacing this Addendum in its entirety to address two 
errors. First, we inadvertently left a discontinued HCPCS code, J1750, 
on Addendum F. This code was replaced by J1751 and J1752 which are 
found on Addendum G ``Revised New Drugs for CAP Bidding for 2006''. 
Second, we included a new HCPCS code, J7318, which we understood would 
replace HCPCS codes J7317 and J7320. HCPCS J7318 was not issued and 
HCPCS codes J7317 & J3120 were retained. We have reweighted and 
corrected Addendum F to reflect these changes.
    These corrections are reflected in Section III.C.6 of this 
correcting amendment.

III. Correction of Errors

    In FR Doc. 05-22160, entitled ``Medicare Program; Revisions to 
Payment Policies Under the Physician Fee Schedule for Calendar Year 
2006 and Certain Provisions Related to the Competitive Acquisition 
Program of Outpatient Drugs and Biologicals Under Part B,'' which 
appeared in the Federal Register on November 21, 2005 (70 FR 70116), 
make the following corrections:

A. Correction of Preamble Errors

    1. On page 70150, in the first column; in the last paragraph under 
Section m. (Additional PE Issues Raised by Commenters), in the second 
sentence, the number ``99755'' is corrected to read ``97755''.
    2. On page 70155, in the center column; the last sentence of the 
second paragraph under the discussion titled, ``3. Cardiac 
Catheterization and

[[Page 9460]]

Angioplasty Exception,'' the number ``93617'' is corrected to read 
``93618''.
    3. On page 70263, in the third column; in the last paragraph, the 
phrase ``Table 26'' is corrected to read ``Table 26A''.
    4. On page 70263, the table heading ``Table 26.--Example of 
Payments'' is corrected to read ``Table 26A.--Example of Payments''.
    5. On page 70274, in the first column; in the second paragraph, the 
paragraph is corrected by adding a new sentence at the end of the 
paragraph to read as follows: ``Because payment for the supplies and 
equipment for both of these procedures is provided under a separate 
DMERC policy, we have deleted the following practice expense items from 
these codes: Supplies deleted include dressings, both Adaptic and 
microporous, the drainage canister, and the sharp debridement kit--
which was identified as not being needed for the typical scenario; and, 
the vacuum pump was deleted from the equipment.''
    6. On page 70282, in the second column; lines 8 through 11, the 
sentence, ``We are assigning a status indicator of N for these services 
because they are noncovered under Medicare.'' is corrected to read, 
``We are assigning a status indicator of B for these services because 
payment for these services is bundled into payment for other Medicare 
services.''
    7. On page 70282, in the third column; we are adding a new 
paragraph before section F. (Establishment of Interim PE RVUs for New 
and Revised Physician's Current Procedural Terminology (CPT) Codes and 
New Healthcare Common Procedure Coding System (HCPCS) Codes for 2006). 
The new paragraph reads as follows: ``CPT code 99339 Individual 
physician supervision of patient (patient not present) in home, 
domiciliary or rest home (e.g., assisted living facility) requiring 
complex and multidisciplinary care modalities involving regular 
physician development and/or revision of care plans, review of 
subsequent reports of patient status, review of related laboratory and 
other studies, communication (including telephone calls) for purposes 
of assessment care decisions with health care professional(s), family 
member(s), surrogate decision maker(s) (e.g., legal guardian) and/or 
key caregiver(s) involved in patient's care, integration of new 
information into the medical treatment plan and/or adjustment of 
medical therapy, within a calendar month; 15-29 minutes.
    CPT code 99340 Individual physician supervision of patient (patient 
not present) in home, domiciliary or rest home (e.g., assisted living 
facility) requiring complex and multidisciplinary care modalities 
involving regular physician development and/or revision of care plans, 
review of subsequent reports of patient status, review of related 
laboratory and other studies, communication (including telephone calls) 
for purposes of assessment care decisions with health care 
professional(s), family member(s), surrogate decision maker(s) (e.g., 
legal guardian) and/or key caregiver(s) involved inpatient's care, 
integration of new information into the medical treatment plan and/or 
adjustment of medical therapy, within a calendar month; 30 minutes or 
more. We are assigning a status indicator of B for these codes because 
payment for these services is bundled into payment for other 
services.''
    8. On page 70296, in the second column; in the last paragraph, in 
line 6, the term ``PFS'' is corrected to read ``Code List''.
    9. On page 70302, in Table 35; in the third column titled ``Annual 
Actual Expenditures'', in line 10 (1/1/03-12/31/03) of that column, 
``76.8'' is corrected to read ``78.2''; and in the fifth column titled 
``Cumulative Actual Expenditures'', in line 10 (1/1/03-12/31/03) of 
that column, ``460.6'' is corrected to read ``462.0''.
    10. On page 70316, in the first column; in the third complete 
sentence, the figure ``-0.6'' is corrected to read ``-0.15''.
    11. On page 70320, in the second footnote to Table 49, the figure 
``0.9984'' is corrected to read ``0.9985''.

B. Correction of Regulation Text Errors

List of Subjects

42 CFR Part 405

    Administrative practice and procedure, Health facilities, Health 
professions, Kidney diseases, Medical devices, Medicare, Reporting and 
recordkeeping requirements, Rural areas, X-rays.

42 CFR Part 414

    Administrative practice and procedure, Health facilities, Health 
professions, Kidney diseases, Medicare, Reporting and recordkeeping 
requirements.

42 CFR Part 426

    Administrative practice and procedure, Medicare, Reporting and 
recordkeeping requirements.
    Given the errors summarized in section II.B. of this correcting 
amendment, we are making the following correcting amendments to 42 CFR 
parts 405, 414, and 426:

PART 405--FEDERAL HEALTH INSURANCE FOR THE AGED AND DISABLED

0
1. The authority citation for part 405 continues to read as follows:

    Authority: Secs. 1102, 1861, 1862(a), 1871, 1874, 1881, and 
1886(k) of the Social Security Act (42 U.S.C. 1302, 1395x, 1395y(a), 
1395hh, 1395kk, 1395rr, and 1395ww(k)), and sec. 353 of the Public 
Health Service Act (42 U.S.C. 263a).

0
2. Section 405.2469 is amended by revising paragraph (a)(1) to read as 
follows:


Sec.  405.2469  Federally Qualified Health Centers supplemental 
payments.

* * * * *
    (a) Calculation of supplemental payment. (1) The supplemental 
payment for Federally Qualified Health Center covered services provided 
to Medicare patients enrolled in Medicare Advantage plans is based on 
the difference between--
    (i) Payments received by the center from the Medicare Advantage 
plan as determined on a per visit basis; and
    (ii) The Federally Qualified Health Center's all-inclusive cost-
based per visit rate as set forth in this subpart, less any amount the 
FQHC may charge as described in section 1857(e)(3)(B) of the Act.
* * * * *

PART 414--PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES

0
3. The authority citation for part 414 continues to read as follows:

    Authority: Secs. 1102, 1871, and 1881(b)(1) of the Social 
Security Act (42 U.S.C. 1302, 1395hh, and 1395rr(b)(1)).

0
4. Section 414.906 is amended by revising paragraph (c)(1) introductory 
text to read as follows:


Sec.  414.906  Competitive acquisition program as the basis of payment.

* * * * *
    (c) Computation of payment amount. (1) Except as specified in 
paragraph (c)(2) of this section, payment for CAP drugs is based on 
bids submitted, as a result of the bidding process as described in 
Sec.  414.910. Based on these bids, a single payment amount for each 
CAP drug in the competitive acquisition area is determined on the basis 
of the bids submitted and accepted and updated from the bidding period 
to the payment year. This single payment amount is then updated on an 
annual

[[Page 9461]]

basis based on the approved CAP vendor's reasonable net acquisition 
costs for that category as determined by CMS, based, in part, on 
information disclosed to CMS and limited by the weighted payment amount 
established under section 1847A of the Act across all drugs for which a 
composite bid is required in the category, and limited by the payment 
amount established under section 1847A of the Act for each other drug 
for which the approved CAP vendor submits a bid in accordance with 
Sec.  414.910. Adjustment to the payment amounts may be made more often 
than annually, but no more often than quarterly, in any of the 
following cases:
* * * * *

PART 426--REVIEW OF NATIONAL COVERAGE DETERMINATIONS AND LOCAL 
COVERAGE DETERMINATIONS

0
5. The authority citation for part 426 continues to read as follows:

    Authority: Secs. 1102 and 1871 of the Social Security Act (42 
U.S.C. 1302 and 1395hh).

0
6. Section 426.340 is amended by revising paragraphs (e)(2)(ii) and 
(f)(2)(ii) to read as follows:


Sec.  426.340  Procedures for review of new evidence.

* * * * *
    (e) * * *
    (2) * * *
    (ii) For NCDs, in compliance with the timeframes specified in 
section 1862(1) of the Act, by which CMS completes the reconsideration.
    (f) * * *
    (2) * * *
    (ii) For NCDs, the reconsideration timeframe specified by the 
Board, in compliance with section 1862(l) of the Act.
* * * * *

C. Correction of Addendum Errors

0
Given the errors summarized in Section II.C of this correcting 
amendment, we are making the following corrections to Addendum B, C, D, 
E, and F. These addenda will not appear in the Code of Federal 
Regulations.
0
1. On pages 70337 through 70463, the following entries to Addendum B 
are corrected to read as follows:

                                                           Addendum B.--Relative Value Units (RVUs) and Related Information--Continued
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                  Physician   Nonfacility  Facility PE  Malpractice  Nonfacility    Facility
             CPT 1/HCPCS 2               Mod         Status                Description           work RVUs 3    PE RVUs        RVUs         RVUs        total        total           Global
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
0141T.................................  .....  I................  Perq islet transplant........         0.00         0.00         0.00         0.00         0.00         0.00  XXX
0142T.................................  .....  I................  Open islet transplant........         0.00         0.00         0.00         0.00         0.00         0.00  XXX
0143T.................................  .....  I................  Laparoscopic islet transplant         0.00         0.00         0.00         0.00         0.00         0.00  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
52648.................................  .....  A................  Laser surgery of prostate....        11.19        74.15         4.80         0.79        86.07        16.78  090
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
61630.................................  .....  N................  Intracranial angioplasty.....       +21.08           NA        12.53         2.01           NA        35.62  090
61635.................................  .....  N................  Intracran angioplasty w/stent       +23.08           NA        13.58         2.20           NA        38.86  090
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
88385.................................     26  A................  Eval molecul probes, 51-250..         1.50         0.65           NA         0.06         2.21           NA  XXX
88385.................................     TC  A................  Eval molecul probes, 51-250..         0.00         6.45           NA         0.06         6.51           NA  XXX
88385.................................  .....  A................  Eval molecul probes, 51-250..         1.50         7.10           NA         0.12         8.72           NA  XXX
88386.................................     26  A................  Eval molecul probes, 251-500.         1.88         0.82           NA         0.08         2.78           NA  XXX
88386.................................     TC  A................  Eval molecul probes, 251-500.         0.00         6.23           NA         0.08         6.31           NA  XXX
88386.................................  .....  A................  Eval molecul probes, 251-500.         1.88         7.05           NA         0.16         9.09           NA  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
90760.................................  .....  A................  Hydration iv infusion init...         0.17         1.43           NA         0.07         1.67           NA  XXX
90761.................................  .....  A................  Hydrate iv infusion, add-on..         0.09         0.40           NA         0.04         0.53           NA  ZZZ
90765.................................  .....  A................  Ther/proph/diag iv inf, init.          0.2        11.76           NA         0.07         2.04           NA  XXX
90766.................................  .....  A................  Ther/proph/dg iv inf, add-on.         0.18         0.46           NA         0.04         0.68           NA  ZZZ
90767.................................  .....  A................  Tx/proph/dg addl seq iv inf..         0.19         0.89           NA         0.04         1.12           NA  ZZZ
90768.................................  .....  A................  Ther/diag concurrent inf.....         0.17         0.44           NA         0.04         0.65           NA  ZZZ
90772.................................  .....  A................  Ther/proph/diag inj, sc/im...         0.17         0.31           NA         0.01         0.49           NA  XXX
90773.................................  .....  A................  Ther/proph/diag inj, ia......         0.17         0.31           NA         0.02         0.50           NA  XXX
90774.................................  .....  A................  Ther/proph/diag inj, iv push.         0.18         1.30           NA         0.04         1.52           NA  XXX
90775.................................  .....  A................  Ther/proph/diag inj add-on...         0.10         0.57           NA         0.04         0.71           NA  ZZZ
92626.................................  .....  A................  Eval aud status rehab........         0.00         2.20           NA         0.06         2.26           NA  XXX
92627.................................  .....  A................  Evallaud status rehab add-on.         0.00         0.55           NA          .02         0.57           NA  ZZZ
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
93514.................................  .....  C................  Left heart catheterization...         0.00         0.00         0.00         0.00         0.00         0.00  000
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
96401.................................  .....  A................  Chemo, anti-neopl, sq/im.....          0.2        11.17           NA         0.01         1.39           NA  XXX
96402.................................  .....  A................  Chemo hormon antineopl sq/im.         0.19         1.01           NA         0.01         1.21           NA  XXX
96405.................................  .....  A................  Chemo intralesional, up to 7.         0.52         2.44         0.24         0.03         2.99         0.79  000
96406.................................  .....  A................  Chemo intralesional over 7...         0.80         3.02         0.29         0.03         3.85         1.12  000
96409.................................  .....  A................  Chemo, iv push, sngl drug....         0.24         2.93           NA         0.06         3.23           NA  XXX
96411.................................  .....  A................  Chemo, iv push, addl drug....         0.20         1.61           NA         0.06         1.87           NA  ZZZ
96413.................................  .....  A................  Chemo, iv infusion, 1 hr.....         0.28         4.20           NA         0.08         4.56           NA  XXX
96415.................................  .....  A................  Chemo, iv infusion, addl hr..         0.19         0.77           NA         0.07         1.03           NA  ZZZ
96416.................................  .....  A................  Chemo prolong infuse w/pump..         0.21         4.61           NA         0.08         4.90           NA  XXX
96417.................................  .....  A................  Chemo iv infuse each addl seq          0.2        11.95           NA         0.07         2.23           NA  ZZZ
96420.................................  .....  A................  Chemo, ia, push technique....         0.17         2.67           NA         0.08         2.92           NA  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
96440.................................  .....  A................  Chemotherapy, intracavitary..         2.37         8.15         1.23         0.17    10.693.77          000
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
96450.................................  .....  A................  Chemotherapy, into CNS.......         1.53         6.97         1.29         0.09         8.59         2.91  000
96521.................................  .....  A................  Refill/maint, portable pump..         0.21         3.77           NA         0.06         4.04           NA  XXX
96522.................................  .....  A................  Refill/maint pump/resvr syst.         0.21         2.65           NA         0.06         2.92           NA  XXX
96523.................................  .....  A................  Irrig drug delivery device...         0.04         0.69           NA         0.01         0.74           NA  XXX
96542.................................  .....  A................  Chemotherapy injection.......         0.75         4.26         0.66         0.07         5.08         1.48  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
97606.................................  .....  A................  Neg press wound tx, >50 cm...         0.60         0.35         0.24         0.03         0.98         0.87  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------


[[Page 9462]]


                                                           Addendum B.--Relative Value Units (RVUs) and Related Information--Continued
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                  Physician   Nonfacility  Facility PE  Malpractice  Nonfacility    Facility
             CPT 1/HCPCS 2               Mod         Status                Description           work RVUs 3    PE RVUs        RVUs         RVUs        total        total           Global
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
98960.................................  .....  B................  Self-mgmt educ & train, 1 pt.         0.00         0.00         0.00         0.00         0.00         0.00  XXX
98961.................................  .....  B................  Self-mgmt educ/train, 2-4 pt.         0.00         0.00         0.00         0.00         0.00         0.00  XXX
98962.................................  .....  B................  Self-mgmt educ/train, 5-8 pt.         0.00         0.00         0.00         0.00         0.00         0.00  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
99300.................................  .....  A................  lc, infant pbw 2501-5000 gm..         2.40           NA         0.84         0.15           NA         3.35  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
99324.................................  .....  A................  Domicil/r-home visit new pat.         1.01         0.49           NA         0.05         1.55           NA  XXX
99325.................................  .....  A................  Domicil/r-home visit new pat.         1.52         0.68           NA         0.07         2.27           NA  XXX
99326.................................  .....  A................  Domicil/r-home visit new pat.         2.27         0.92           NA         0.10         3.29           NA  XXX
99327.................................  .....  A................  Domicil/r-home visit new pat.         3.03         1.17           NA         0.13         4.33           NA  XXX
99328.................................  .....  A................  Domicil/r-home visit new pat.         3.78         1.42           NA         0.16         5.36           NA  XXX
99334.................................  .....  A................  Domicil/r-home visit est pat.         0.76         0.40           NA         0.04         1.20           NA  XXX
99335.................................  .....  A................  Domicil/r-home visit est pat.         1.26         0.58           NA         0.06         1.90           NA  XXX
99336.................................  .....  A................  Domicil/r-home visit est pat.         2.02         0.82           NA         0.09         2.93           NA  XXX
99337.................................  .....  A................  Domicil/r-home visit est pat.         3.03         1.15           NA         0.13         4.31           NA  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
99340.................................  .....  B................  Domicil/r-home care supervis.         0.00         0.00         0.00         0.00         0.00         0.00  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
G0332.................................  .....  A................  Preadmin IV immunoglobulin...         0.00         1.91           NA         0.00         1.91           NA  XXX
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
\2\ Copyright 2005 American Dental Association. All Rights Reserved.
\3\ Indicates RVUs are not used for Medicare payment.

    2. On page 70463, the following entries to Addendum B, G9041, 
G9042, G9043, and G9044 are removed.

                                                           Addendum B.--Relative Value Units (RVUs) and Related Information--Continued
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                  Physician
           CPT \1\/HCPCS \2\             Mod         Status                Description            work RVUs   Nonfacility  Facility PE  Malpractice  Nonfacility    Facility         Global
                                                                                                     \3\        PE RVUs        RVUs         RVUs        total        total
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
G9041.................................  .....  X................  Low vision rehab occupationa.         0.00         0.00         0.00         0.00         0.00         0.00  XXX
G9042.................................  .....  X................  Low vision rehab orient/mobi.         0.00         0.00         0.00         0.00         0.00         0.00  XXX
G9043.................................  .....  X................  Low vision lowvision therapy.         0.00         0.00         0.00         0.00         0.00         0.00  XXX
G9044.................................  .....  X................  Low vision rehabilate teache.         0.00         0.00         0.00         0.00         0.00         0.00  XXX
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
\2\ Copyright 2005 American Dental Association. All Rights Reserved.
\3\ +Indicates RVUs are not used for Medicare payment.


0
3. On pages 70463 through 70466, the following entries to Addendum C 
are corrected to read as follows:

                                                                              Addendum C.--Codes With Interim RVUs
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                  Physician
          CPT \1\/ HCPCS \2\             Mod         Status                Description            work RVUs   Nonfacility  Facility PE  Malpractice  Nonfacility    Facility         Global
                                                                                                     \3\        PE RVUs        RVUs         RVUs        Total        Total
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
61630.................................  .....  N................  Intracranial angioplasty.....       +21.08           NA        12.53         2.01           NA        35.62  090
61635.................................  .....  N................  Intracran angioplasty w/stent       +23.08           NA        13.58         2.20           NA        30.66  090
88385.................................     26  A................  Eval Molecul probes, 51-250..         1.50         0.65           NA         0.06         2.21           NA  XXX
88386.................................     26  A................  Eval Molecul probes, 251-500.         1.88         0.82           NA         0.08         2.78           NA  XXX
90760.................................  .....  A................  Hydration iv infusion, init..         0.17         1.43           NA         0.07         1.67           NA  XXX
90761.................................  .....  A................  Hydrate iv infusion, add-on..         0.09         0.40           NA         0.04         0.53           NA  ZZZ
90765.................................  .....  A................  Ther/proph/diag iv inf, init.         0.21         1.76           NA         0.07         2.04           NA  XXX
90766.................................  .....  A................  Ther/proph/dg iv inf, add-on.         0.18         0.46           NA         0.04         0.68           NA  ZZZ
90767.................................  .....  A................  Tx/proph/dg addl seq iv inf..         0.19         0.89           NA         0.04         1.12           NA  ZZZ
90768.................................  .....  A................  Ther/diag concurrent inf.....         0.17         0.44           NA         0.04         0.65           NA  ZZZ
90772.................................  .....  A................  Ther/proph/diag inj, sc/im...         0.17         0.31           NA         0.01         0.49           NA  XXX
90773.................................  .....  A................  Ther/proph/diag inj, ia......         0.17         0.31           NA         0.02         0.50           NA  XXX
90774.................................  .....  A................  Ther/proph/diag inj, iv push.         0.18         1.30           NA         0.04         1.52           NA  XXX
90775.................................  .....  A................  Ther/proph/diag inj add-on...         0.10         0.57           NA         0.04         0.71           NA  ZZZ
92626.................................  .....  A................  Eval aud status rehab........         0.00         2.20           NA         0.06         2.26           NA  XXX
92627.................................  .....  A................  Evalaud status rehab add-on..         0.00         0.55           NA         0.02         0.57           NA  ZZZ
96401.................................  .....  A................  Chemo, anti-neopl, sq/im.....         0.21         1.17           NA         0.01         1.39           NA  XXX
96402.................................  .....  A................  Chemo hormone antineopl sq/im         0.19         1.01           NA         0.01         1.21           NA  XXX
96409.................................  .....  A................  Chemo, iv push, sngl drug....         0.24         2.93           NA         0.06         3.23           NA  XXX
96411.................................  .....  A................  Chemo, iv push, addl drug....         0.20         1.61           NA         0.06         1.87           NA  ZZZ
96413.................................  .....  A................  Chemo, iv infusion, 1 hr.....         0.28         4.20           NA         0.08         4.56           NA  XXX
96415.................................  .....  A................  Chemo, iv infusion, addl hr..         0.19         0.77           NA         0.07         1.03           NA  ZZZ
96416.................................  .....  A................  Chemo prolong infuse w/pump..         0.21         4.61           NA         0.08         4.90           NA  XXX
96417.................................  .....  A................  Chemo iv infuse each addl seq         0.21         1.95           NA         0.07         2.23           NA  ZZZ
96450.................................  .....  A................  Chemotherapy, into CNS.......         1.53         6.97         1.29         0.09         8.59         2.91  000

[[Page 9463]]

 
96521.................................  .....  A................  Refill/maint, portable pump..         0.21         3.77           NA         0.06         4.04           NA  XXX
96522.................................  .....  A................  Refil/maint pump/resvr syst..         0.21         2.65           NA         0.06         2.92           NA  XXX
96523.................................  .....  A................  Irrig drug delivery device...         0.04         0.69           NA         0.01         0.74           NA  XXX
96542.................................  .....  A................  Chemotherapy injection.......         0.75         4.26         0.66         0.07         5.08         1.48  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
98960.................................  .....  B................  Self-mgmt educ & train, 1 pt.         0.00         0.00         0.00         0.00         0.00         0.00  XXX
98961.................................  .....  B................  Self-mgmt educ/train, 2-4 pt.         0.00         0.00         0.00         0.00         0.00         0.00  XXX
98962.................................  .....  B................  Self-mgmt educ/train 5-8 pt..         0.00         0.00         0.00         0.00         0.00         0.00  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
99300.................................  .....  A................  Ic, infant pbw 2501-5000 gm..         2.40           NA         0.84         0.15           NA         3.35  XXX
99324.................................  .....  A................  Domicil/r-home visit new pat.         1.01         0.49           NA         0.05         1.55           NA  XXX
99325.................................  .....  A................  Domicil/r-home visit new pat.         1.52         0.68           NA         0.07         2.27           NA  XXX
99326.................................  .....  A................  Domicil/r-home visit new pat.         2.27         0.92           NA         0.10         3.29           NA  XXX
99327.................................  .....   A...............  Domicil/r-home visit new pat.         3.03         1.17           NA         0.13         4.33           NA  XXX
99328.................................  .....  A................  Domicil/r-home visit new pat.         3.78         1.42           NA         0.16         5.36           NA  XXX
99334.................................  .....  A................  Domicil/r-home visit est pat.         0.76         0.40           NA         0.04         1.20           NA  XXX
99335.................................  .....  A................  Domicil/r-home visit est pat.         1.26         0.58           NA         0.06         1.90           NA  XXX
99336.................................  .....  A................  Domicil/r-home visit est pat.         2.02         0.82           NA         0.09         2.93           NA  XXX
99337.................................  .....  A................  Domicil/r-home visit est pat.         3.03         1.15           NA         0.13         4.31           NA  XXX
                                        .....  .................  .............................  ...........  ...........  ...........  ...........  ...........  ...........  .................
99340.................................  .....  B................  Domicil/r-home care supervis.         0.00         0.00         0.00         0.00         0.00         0.00  XXX
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
\2\ Copyright 2005 American Dental Association. All Rights Reserved.
\3\ +Indicates RVUs are not used for Medicare payment.


0
4. On page 70467, in Addendum D, in the 11th entry, in the third 
column, the locality ``Kansas*'' is corrected to read ``Kansas'' as 
follows:

         Addendum D.--2006 Geographic Practice Cost Indices by Medicare Carrier and Locality--Continued
----------------------------------------------------------------------------------------------------------------
               Carrier                  Locality        Locality name       Work GPCI     PE GPCI      MP GPCI
----------------------------------------------------------------------------------------------------------------
00650...............................           00  Kansas................        1.000        0.878        0.721
----------------------------------------------------------------------------------------------------------------


0
5. On page 70469, in Addendum E, in the fourth entry, in the third 
column, the locality ``Kansas*'' is corrected to read ``Kansas'' as 
follows:

                    Addendum E.--2006 GAFs--Continued
------------------------------------------------------------------------
           Carrier               Locality    Locality name     2006 GAF
------------------------------------------------------------------------
00650........................           00  Kansas.........       0.0936
------------------------------------------------------------------------


0
6. On pages 70469 through 70471, Addendum F, in its entirety, is 
corrected to read as follows:

             Addendum F.--Revised Single Drug Category List
------------------------------------------------------------------------
             HCPCS                   Long description         Weight
------------------------------------------------------------------------
J0150..........................  Injection, adenosine         0.00070000
                                  for therapeutic use, 6
                                  mg.
J0152..........................  Injection, adenosine         0.00459478
                                  for diagnostic use, 30
                                  mg.
J0170..........................  Injection, adrenalin,        0.00007897
                                  epinephrine, 1 ml
                                  ampule.
J0207..........................  Injection, amifostine,       0.00016099
                                  500 mg.
J0215..........................  Injection, alefacept,        0.00083383
                                  0.5 mg.
J0280..........................  Injection,                   0.00082088
                                  aminophyllin, 250 mg.
J0290..........................  Injection, ampicillin        0.00012657
                                  sodium, 500 mg.
J0475..........................  Injection, baclofen, 10      0.00024643
                                  mg.
J0540..........................  Injection, penicillin g      0.00007209
                                  benzathine and
                                  penicillin g procaine,
                                  1,200,000 units.
J0550..........................  Injection, penicillin g      0.00001831
                                  benzathine and
                                  penicillin g procaine,
                                  2,400,000 units.
J0570..........................  Injection, penicillin g      0.00004605
                                  benzathine, 1,200,000
                                  units.
J0585..........................  Botulinum toxin type A,      0.03743206
                                  per unit.
J0587..........................  Botulinum toxin type B,      0.00150704
                                  per 100 units.
J0600..........................  Injection, edetate           0.00004459
                                  calcium disodium, 1000
                                  mg.
J0637..........................  Injection, caspofungin       0.00008483
                                  acetate, 5 mg.
J0640..........................  Injection, leucovorin        0.01064503
                                  calcium, per 50 mg.
J0670..........................  Injection, mepivacaine       0.00038398
                                  hydrochloride, per 10
                                  ml.

[[Page 9464]]

 
J0690..........................  Injection, cefazolin         0.00042410
                                  sodium, 500 mg.
J0692..........................  Injection, cefepime          0.00024846
                                  hydrochloride, 500 mg.
J0696..........................  Injection, ceftriaxone       0.00668833
                                  sodium, per 250 mg.
J0698..........................  Injection, cefotaxime        0.00014878
                                  sodium, per gm.
J0702..........................  Injection,                   0.00287709
                                  betamethasone acetate
                                  & betamethasone sodium
                                  phosphate, per 3 mg.
J0704..........................  Injection,                   0.00057059
                                  betamethasone sodium
                                  phosphate, per 4 mg.
J0735..........................  Injection, clonidine         0.00034149
                                  hydrochloride, 1 mg.
J0800..........................  Injection,                   0.00363945
                                  corticotropin, 40
                                  units.
J0881..........................  Injection, darbepoetin       0.15953454
                                  alfa, 1 mcg (non-ESRD
                                  use).
J0885..........................  Injection, epoetin           0.25136609
                                  alpha, (for non ESRD
                                  use), per 1000 units.
J0895..........................  Injection, deferoxamine      0.00024448
                                  mesylate, 500 mg.
J1000..........................  Injection, depo-             0.00021013
                                  estradiol cypionate, 5
                                  mg.
J1020..........................  Injection,                   0.00127329
                                  methylprednisolone
                                  acetate, 20 mg.
J1030..........................  Injection,                   0.00593138
                                  methylprednisolone
                                  acetate, 40 mg.
J1040..........................  Injection,                   0.00527803
                                  methylprednisolone
                                  acetate, 80 mg.
J1051..........................  Injection,                   0.00006526
                                  medroxyprogesterone
                                  acetate, 50 mg.
J1094..........................  Injection,                   0.00351268
                                  dexamethasone acetate,
                                  1 mg.
J1100..........................  Injection,                   0.05492057
                                  dexamethasone sodium
                                  phosphate, 1 mg.
J1190..........................  Injection, dexrazoxane       0.00002444
                                  hydrochloride, per 250
                                  mg.
J1200..........................  Injection,                   0.00216491
                                  diphenhydramine hcl,
                                  50 mg.
J1212..........................  Injection, DMSO,             0.00008475
                                  dimethyl sulfoxide,
                                  50%, 50 ml.
J1245..........................  Injection,                   0.00383178
                                  dipyridamole, per 10
                                  mg.
J1250..........................  Injection, dobutamine        0.00053182
                                  hydrochloride, per 250
                                  mg.
J1260..........................  Injection, dolasetron        0.01737101
                                  mesylate, 10 mg.
J1335..........................  Injection, ertapenem         0.00013263
                                  sodium, 500 mg.
J1440..........................  Injection, filgrastim        0.00193572
                                  (G-CSF), 300 mcg.
J1441..........................  Injection, filgrastim        0.00407388
                                  (G-CSF), 480 mcg.
J1450..........................  Injection fluconazole,       0.00001609
                                  200 mg.
J1580..........................  Injection, garamycin,        0.00039937
                                  gentamicin, 80 mg.
J1600..........................  Injection, gold sodium       0.00005613
                                  thiomalate, 50 mg.
J1626..........................  Injection, granisetron       0.01483731
                                  hydrochloride, 100 mcg.
J1631..........................  Injection, haloperidol       0.00020702
                                  decanoate, per 50 mg.
J1642..........................  Injection, heparin           0.06422737
                                  sodium, (heparin lock
                                  flush), per 10 units.
J1644..........................  Injection, heparin           0.00354562
                                  sodium, per 1000 units.
J1645..........................  Injection, dalteparin        0.00011526
                                  sodium, per 2500 iu.
J1650..........................  Injection, enoxaparin        0.00135618
                                  sodium, 10 mg.
J1655..........................  Injection, tinzaparin        0.00047170
                                  sodium, 1000 iu.
J1720..........................  Injection,                   0.00013327
                                  hydrocortisone sodium
                                  succinate, 100 mg.
J1745..........................  Injection infliximab,        0.02762721
                                  10 mg.
J1756..........................  Injection, iron              0.01026994
                                  sucrose, 1 mg.
J1885..........................  Injection, ketorolac         0.00330082
                                  tromethamine, per 15
                                  mg.
J1940..........................  Injection, furosemide,       0.00065369
                                  20 mg.
J1956..........................  Injection,                   0.00008629
                                  levofloxacin, 250 mg.
J2001..........................  Injection, lidocaine         0.00077528
                                  hcl for intravenous
                                  infusion, 10 mg.
J2010..........................  Injection, lincomycin        0.00062461
                                  hcl, 300 mg.
J2150..........................  Injection, mannitol,         0.00029211
                                  25% in 50 ml.
J2260..........................  Injection, milrinone         0.00004959
                                  lactate, 5 mg.
J2300..........................  Injection, nalbuphine        0.00026341
                                  hydrochloride, per 10
                                  mg.
J2325..........................  Injection, nesiritide,       0.00027406
                                  0.1 mg.
J2353..........................  Injection, octreotide,       0.00195107
                                  depot form for
                                  intramuscular
                                  injection, 1 mg.
J2354..........................  Injection, octreotide,       0.00008412
                                  non-depot subcutaneous
                                  or intravenous
                                  injection, 25 mcg.
J2405..........................  Injection, ondansetron       0.01373037
                                  hydrochloride, per 1
                                  mg.
J2430..........................  Injection, pamidronate       0.00156790
                                  disodium, per 30 mg.
J2505..........................  Injection,                   0.00065114
                                  pegfilgrastim, 6 mg.
J2550..........................  Injection, promethazine      0.00068681
                                  hcl, 50 mg.
J2680..........................  Injection, fluphenazine      0.00015113
                                  decanoate, 25 mg.
J2765..........................  Injection,                   0.00011134
                                  metoclopramide hCL, 10
                                  mg.
J2780..........................  Injection, ranitidine        0.00088550
                                  hydrochloride, 25 mg.
J2820..........................  Injection, sargramostim      0.00217910
                                  (GM-CSF), 50 mcg.
J2912..........................  Injection, sodium            0.00680009
                                  chloride, 0.9%, per 2
                                  ml.
J2916..........................  Injection, sodium            0.00061134
                                  ferric gluconate
                                  complex in sucrose
                                  injection, 12.5 mg.
J2920..........................  Injection,                   0.00031230
                                  methylprednisolone
                                  sodium succinate, 40
                                  mg.
J2930..........................  Injection,                   0.00077199
                                  methylprednisolone
                                  sodium succinate, 125
                                  mg.
J2997..........................  Injection, alteplase         0.00012239
                                  recombinant, 1 mg.
J3260..........................  Injection, tobramycin        0.00018292
                                  sulfate, 80 mg.
J3301..........................  Injection,                   0.02166537
                                  triamcinolone
                                  acetonide, per 10 mg.
J3302..........................  Injection,                   0.00173214
                                  triamcinolone
                                  diacetate, per 5 mg.
J3303..........................  Injection,                   0.00094603
                                  triamcinolone
                                  hexacetonide, per 5 mg.
J3315..........................  Injection, triptorelin       0.00000713
                                  pamoate, 3.75 mg.
J3370..........................  Injection, vancomycin        0.00084187
                                  hCL, 500 mg.
J3396..........................  Injection, verteporfin,      0.05438624
                                  0.1 mg.
J3410..........................  Injection, hydroxyzine       0.00041004
                                  hCL, 25 mg.

[[Page 9465]]

 
J3420..........................  Injection, vitamin B-12      0.01203050
                                  cyanocobalamin, up to
                                  1000 mcg.
J3475..........................  Injection, magnesium         0.00108505
                                  sulfate, per 500 mg.
J3480..........................  Injection, potassium         0.00215709
                                  chloride, per 2 meq.
J3487..........................  Injection, zoledronic        0.00336479
                                  acid, 1 mg.
J7030..........................  Infusion, normal saline      0.00102834
                                  solution, 1000 cc.
J7040..........................  Infusion, normal saline      0.00243166
                                  solution, sterile (500
                                  ml = 1 unit).
J7042..........................  5% dextrose/normal           0.00049872
                                  saline (500 ml = 1
                                  unit).
J7050..........................  Infusion, normal saline      0.00993344
                                  solution, 250 cc.
J7060..........................  5% dextrose/water (500       0.00102860
                                  ml = 1 unit).
J7070..........................  Infusion, D5W, 1000 cc.      0.00015894
J7120..........................  Ringers lactate              0.00016980
                                  infusion, 1000 cc.
J7317..........................  Sodium hyaluronate, per      0.00191598
                                  20 to 25 mg dose for
                                  intra-articular
                                  injection.
J7320..........................  Hylan G-F 20, 16 mg,         0.00149854
                                  for intra articular
                                  injection.
J9000..........................  Doxorubicin hCL, 10 mg.      0.00235846
J9001..........................  Doxorubicin                  0.00032536
                                  hydrochloride, all
                                  lipid formulations, 10
                                  mg.
J9031..........................  BCG (Intravesical) per       0.00049267
                                  instillation.
J9040..........................  Bleomycin sulfate, 15        0.00003728
                                  units.
J9045..........................  Carboplatin, 50 mg.....      0.00570096
J9050..........................  Carmustine, 100 mg.....      0.00000890
J9060..........................  Cisplatin, powder or         0.00095393
                                  solution, per 10 mg.
J9062..........................  Cisplatin, 50 mg.......      0.00025430
J9065..........................  Injection, cladribine,       0.00008142
                                  per 1 mg.
J9070..........................  Cyclophosphamide, 100        0.00062691
                                  mg.
J9080.........................
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.